15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Puma Biotechnology Inc, 0 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $6.00 to $6.00, so the covering firms are broadly aligned. The average target of $6.00 sits 37% below the current $9.56. The rating mix has stayed broadly stable, with Buy-side ratings easing from 1 to 0 over recent months.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Hold
Strong Buy00%
Buy00%
Hold1100%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Puma Biotechnology Inc.
As of Sep, 0 of 1 firms rate PBYI a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PBYI EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 0 analysts
Next period, 0 analysts expect Puma Biotechnology Inc to earn — a share (range — – —), versus — a year earlier.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 0 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Puma Biotechnology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PBYI.
#1
EW
Edward White
HC Wainwright & Co. · Rank #290
Buy
$7.00-26.8% to target
Overall win rate
31%
+ Follow
#2
MF
Marc Frahm
TD Cowen
Hold
$6.00-37.2% to target
Coverage
—
+ Follow
#3
Gena Wang
Barclays
Sell
$2.00-79.1% to target
Coverage
—
+ Follow
PBYI stock forecast FAQ
What is PBYI's average 12-month price target?+
The 1 analysts with a live target average $6.00 for Puma Biotechnology Inc over the next 12 months, ranging from a $6.00 high to a $6.00 low.
Is PBYI stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 1 analyst ratings, 0 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover PBYI?+
1 analysts have an active rating on Puma Biotechnology Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering PBYI?+
Among analysts who currently cover PBYI, Edward White of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #290). Their current call is Buy with a $7.00 target.
What is Puma Biotechnology Inc's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 0 analysts. Full-year EPS is projected at —, rising to — the following year.
How much revenue is Puma Biotechnology Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading PBYI lately?+
As of Sep, 0 of 1 firms rate PBYI a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PBYI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
